2024-10-26 - Analysis Report
## Pfizer Inc. (PFE) Stock Analysis Report

**Company Overview:** Pfizer Inc. is a global pharmaceutical company that develops and manufactures medicines and vaccines.

**Performance Analysis:**

**1. Relative Performance vs. S&P 500:**

* **Cumulative Return:** PFE: -12.82%, VOO (S&P 500): 135.48%
* **Performance Gap:** PFE is lagging behind VOO by **-148.3%**. This means PFE has underperformed VOO significantly over the considered period.
* **Relative Strength (S.R.):** 0.87. This suggests that PFE's current performance is within the 87th percentile of its historical performance range relative to VOO.

**2. Recent Price Movements:**

* **Closing Price:** $28.64
* **5-Day Moving Average:** $28.9
* **20-Day Moving Average:** $29.06
* **60-Day Moving Average:** $29.1

PFE is currently trading below all three moving averages, indicating a downward trend in the short-term.

**3. Technical Indicators:**

* **RSI:** 50.68 – The RSI is currently in neutral territory, suggesting neither strong overbought nor oversold conditions.
* **PPO:** -0.22 – The PPO is negative, indicating a potential bearish momentum.
* **20-day Relative Divergence:** +0.87 – This indicates a short-term upward trend in the relative performance of PFE compared to its past 20-day performance.
* **Expected Return:** 0.0% – PFE is expected to perform in line with the S&P 500 over the next two years, offering no significant outperformance.

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-30 | 0.6 | 0.458 |
| 2024-05-01 | 0.82 | 0.516 |
| 2024-01-30 | 0.1 | -0.19 |
| 2023-10-31 | -0.17 | -0.32 |
| 2023-08-01 | 0.67 | 0.56 |

Pfizer's latest earnings report for Q2 2024 surpassed analysts' expectations, with EPS of 0.60 exceeding the expected 0.458. This positive surprise suggests strong performance despite ongoing macroeconomic challenges. However, historical data shows inconsistent performance, with some quarters showing significant deviations from expectations. 

**5. News and Recent Issues:**

* **Earnings News:** No recent earnings news was found on Shacknews or other major financial news sources.
* **Market Outlook:** FINBOLD forecasts a positive outlook for PFE, citing the company's strong revenue growth and market dominance in the vaccine and drug industries. 
* **Analyst Opinions:** Several analysts have recently given PFE a "buy" rating, emphasizing the company's strong financial performance and growth prospects in the healthcare sector.

**6. Overall Analysis:**

PFE has significantly underperformed the S&P 500 in the past, but its recent earnings beat and positive analyst sentiment suggest potential for recovery. While technical indicators point to a neutral to slightly bearish short-term outlook, the company's strong financial position and future growth opportunities warrant further consideration for long-term investors. 

**7. Recommendation:**

PFE's recent performance suggests it is not suitable for short-term traders. However, long-term investors seeking exposure to the healthcare sector may consider adding PFE to their portfolios.  However, it is essential to monitor future earnings reports and analyst recommendations closely to gauge the company's long-term performance trajectory.

**Disclaimer:** This analysis is based on publicly available information and should not be considered financial advice. Please consult with a qualified financial advisor before making any investment decisions. 
